Skip to main content
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published loading...Updated

TelevisaUnivision Announces Fourth Quarter and Full Year 2025 Results

TelevisaUnivision reduced its 2025 losses to $235 million with ViX streaming profits offsetting a 11% drop in U.S. advertising revenue, CEO Alegre said.

  • On Feb. 23, 2026 BioMarin announced full-year 2025 results and provided 2026 guidance, with revenues expected to be $3,325 to $3,425 million.
  • VOXZOGO's sales surged, driving 17% total revenue growth in 2025, while Enzyme Therapies advanced 9%, supported by PALYNZIQ, and BioMarin expanded VOXZOGO CANOPY with five new indications.
  • Full-Year GAAP results show a net loss of $ million, while non-GAAP results reported $47.7 million net income and a 16.5% gross margin for 2025.
  • The acquisition of Amicus Therapeutics, expected to close in Q2'26, includes $3.7 billion in financing, and management expects a Non‑GAAP Operating Margin of approximately 40% for 2026, excluding the post-close impact.
  • Upcoming regulatory dates include a PALYNZIQ U.S. PDUFA date on February 28, 2026, and other 1H'26 program milestones; the press release contains extensive forward‑looking statements subject to risks, BioMarin said.
Insights by Ground AI

40 Articles

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 44% of the sources are Center
44% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

The Hamilton Spectator broke the news in Hamilton, Canada on Monday, February 23, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal